Electrocardiography

Global ECG Equipment and Management Systems Industry to 2027 - Key Market Trends and Drivers - ResearchAndMarkets.com

Retrieved on: 
Friday, June 18, 2021

The "ECG Equipment and Management Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "ECG Equipment and Management Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for ECG Equipment and Management Systems estimated at US$5.4 Billion in the year 2020, is projected to reach a revised size of US$8 Billion by 2027, growing at a CAGR of 5.8% over the analysis period 2020-2027.
  • Resting ECG System, one of the segments analyzed in the report, is projected to record a 5.7% CAGR and reach US$4.5 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 9.3% CAGR
    The ECG Equipment and Management Systems market in the U.S. is estimated at US$1.4 Billion in the year 2020.

Worldwide Medical Electrodes Industry to 2026 - by Type and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, June 14, 2021

Parkinson's Foundation, a nonprofit organization, stated that currently, 10.0 Mn individuals across the globe are living with Parkinson's disease.

Key Points: 
  • Parkinson's Foundation, a nonprofit organization, stated that currently, 10.0 Mn individuals across the globe are living with Parkinson's disease.
  • Electrocardiography electrodes are portable, conductive, and adhesive in nature, thereby are highly used in capturing and storing patients' heartbeats.
  • What are the current market trends and dynamics in the medical electrodes market and valuable opportunities for emerging players?
  • Are low and middle-income economies investing in the medical electrodes market?

vMap™’s Role in Optimizing Non-Invasive Radio-Ablation Therapy presented at ACC.21 and THRS 2021

Retrieved on: 
Thursday, June 10, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210610005300/en/
    The study found vMap was capable of localizing ventricular tachycardia exit sites for all study patients.
  • And, for the patients who were eligible for invasive mapping, vMap was able to identify the correct anatomic segment in 100% of cases.
  • Presented by its lead author Dr. Gordon Ho at American College of Cardiology 2021 and the Taiwan Heart Rhythm Society 2021 (THRS), the research won first prize in the Clinical - Ventricular Arrhythmias/Cardiac Implanted Electronic Device category at THRS.
  • About vMap: vMap is a proprietary, non-invasive arrhythmia mapping technology that analyzes the information contained in a patients standard ECG.

Cardiac Insight Awarded Wearable Medical Devices and Mobile Medical Applications Category Group Purchasing Agreement with Premier

Retrieved on: 
Monday, June 7, 2021

Cardiac Insight , Inc. (Cardiac Insight or the Company) is a healthcare innovator specializing in wearable cardiac sensors and proprietary software that automatically analyzes electrocardiogram (ECG) data to detect arrythmias, including atrial fibrillation.

Key Points: 
  • Cardiac Insight , Inc. (Cardiac Insight or the Company) is a healthcare innovator specializing in wearable cardiac sensors and proprietary software that automatically analyzes electrocardiogram (ECG) data to detect arrythmias, including atrial fibrillation.
  • The Company announced today that it has been awarded a Group Purchasing Agreement in the Wearable Medical Devices and Mobile Medical Applications category with Premier, Inc .
  • View the full release here: https://www.businesswire.com/news/home/20210607005583/en/
    This is a major milestone for Cardiac Insight.
  • We are excited to support Premiers efforts to enhance patient care, says Bob Odell, Cardiac Insight President and Chief Operating Officer.

Cardiac Insight Announces Expansion Into More Than 20 Asia-Pacific Markets with i.SigNal by Dreamtech Partnership

Retrieved on: 
Thursday, June 3, 2021

The Cardea SOLO System is a standalone solution and does not require internet access, cloud computing solutions or third-party outsourcing.

Key Points: 
  • The Cardea SOLO System is a standalone solution and does not require internet access, cloud computing solutions or third-party outsourcing.
  • Cardiac Insights market-disrupting ECG patch technology delivers compelling value to Korea and Asia-Pacific markets by providing increased productivity to health care systems.
  • ABOUT CARDIAC INSIGHT, INC: Cardiac Insight, Inc. ( www.cardiacinsightinc.com ) is a leading U.S. digital healthcare innovation company specializing in the development of medical-grade, body-worn ECG sensor technology and automated cardiac analysis solutions through its proprietary algorithms and software platforms.
  • Follow Cardiac Insight on Twitter and LinkedIn for the latest news and information.

Spacelabs Healthcare Introduces Lifescreen Pro for Rapid Analysis of Arrhythmia Events

Retrieved on: 
Tuesday, May 25, 2021

Spacelabs Healthcare (the Company or Spacelabs), a division of OSI Systems, Inc. (OSI Systems) (NASDAQ: OSIS), today announced the release of Lifescreen Pro event screening system.

Key Points: 
  • Spacelabs Healthcare (the Company or Spacelabs), a division of OSI Systems, Inc. (OSI Systems) (NASDAQ: OSIS), today announced the release of Lifescreen Pro event screening system.
  • Lifescreen Pro expands the Companys non-invasive cardiology offerings, which include Spacelabs Pathfinder SL ambulatory ECG analysis system.
  • Cardiologists need rapid and actionable data analysis to ensure their patients are on the right care path, without delay.
  • Lifescreen Pro provides rapid analysis, allowing an initial triage to find suspected or intermittent arrhythmia events.

ITC Formally Commences Investigation into Apple Watch Infringement of AliveCor Patents

Retrieved on: 
Friday, May 21, 2021

b'MOUNTAIN VIEW, Calif., May 21, 2021 /PRNewswire/ -- AliveCor , a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services, today announced that the US International Trade Commission (ITC) issued a Notice of Institution of an Investigation into Apple\'s alleged infringement of three AliveCor patents.

Key Points: 
  • b'MOUNTAIN VIEW, Calif., May 21, 2021 /PRNewswire/ -- AliveCor , a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services, today announced that the US International Trade Commission (ITC) issued a Notice of Institution of an Investigation into Apple\'s alleged infringement of three AliveCor patents.
  • Last month, AliveCor filed the case with ITC, alleging the infringement and seeking to bar the importation of Apple Watches incorporating the infringing technology into the United States.\nThe ITC announcement came late Thursday and commences an inquiry into whether Apple illegally incorporated AliveCor\'s patented electrocardiogram monitor technology into the Apple Watch.\nAliveCor, Inc. is transforming cardiological care using deep learning.
  • AliveCor protects its customers with stringent data security and compliance practices , achieving HIPAA compliance and SOC2 Type 1 and Type 2 attestations.
  • AliveCor is a privately-held company headquartered in Mountain View, Calif. "Consumer" or "Personal" ECGs are ECG devices available for direct sale to consumers.

CardioComm Solutions Completes Issuance of Shares for Debt

Retrieved on: 
Wednesday, May 12, 2021

b'Toronto, Ontario--(Newsfile Corp. - May 12, 2021) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announced that it has completed its previously announced issuance of shares for debt (see the Company\'s press releases dated April 27, 2021 and April 8, 2021 for further details).\nUnder debt settlement agreements, the Company has issued an aggregate of 3,353,644 common shares of the Company ("Shares") to directors, employees and consultants of the Company to settle debt for services provided to the Company.

Key Points: 
  • b'Toronto, Ontario--(Newsfile Corp. - May 12, 2021) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, announced that it has completed its previously announced issuance of shares for debt (see the Company\'s press releases dated April 27, 2021 and April 8, 2021 for further details).\nUnder debt settlement agreements, the Company has issued an aggregate of 3,353,644 common shares of the Company ("Shares") to directors, employees and consultants of the Company to settle debt for services provided to the Company.
  • Products are sold worldwide through a combination of an external distribution network and a North American-based sales team.
  • CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).\nFOR FURTHER INFORMATION PLEASE CONTACT:\nThis release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items.
  • Such statements and information reflect management\'s current beliefs and are based on information currently available to management.

The Feasibility of 12-Lead Computational Analysis in Patients after COVID-19 Infection, using Vektor Medical’s vMap™, presented at Taiwan Heart Rhythm Society (THRS) 2021 Cutting-Edge Care for Heart Rhythm

Retrieved on: 
Wednesday, May 5, 2021

announced that a single-center study conducted at the University of California San Diego reports that use of vMap\xe2\x84\xa2 (computational 12-lead ECG analysis) is feasible in patients following infection from COVID-19.

Key Points: 
  • announced that a single-center study conducted at the University of California San Diego reports that use of vMap\xe2\x84\xa2 (computational 12-lead ECG analysis) is feasible in patients following infection from COVID-19.
  • The study , presented as part of THRS 2021 Cutting-Edge Care for Heart Rhythm on April 17-18, evaluated five patients 1.8\xc2\xb11.1 months after COVID-19 diagnosis.\nCOVID-19 is associated with myocardial inflammation which may cause or exacerbate arrhythmias.
  • Seven clinical arrhythmias were evaluated in the five patients who had experienced COVID-19; including atrial flutter, atrial fibrillation, and ventricular tachycardia.
  • Vektor Medical is in the process of applying for FDA clearance for vMap\xe2\x84\xa2, which is not currently available for distribution.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210505005409/en/\n'

Global Mobile Cardiac Telemetry Systems Market (2020 to 2025) - by Technology, Type, Application, End-user and Geography - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 21, 2021

Jul-2020: Biotricity signed partnership agreement with Verizon for developing EMS solutions for First Responders by integrating its Bioflux solution.

Key Points: 
  • Jul-2020: Biotricity signed partnership agreement with Verizon for developing EMS solutions for First Responders by integrating its Bioflux solution.
  • Bioflux is a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of patients' ECG information.
  • The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size.
  • The projections are calculated using proven research methodologies.\nThe report has been compiled through extensive primary and secondary research.